Premium
CRISPR/Cas9 nickase‐mediated efficient and seamless knock‐in of lethal genes in the medaka fish Oryzias latipes
Author(s) -
Murakami Yu,
Futamata Ryota,
Horibe Tomohisa,
Ueda Kazumitsu,
Kinoshita Masato
Publication year - 2020
Publication title -
development, growth and differentiation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 66
eISSN - 1440-169X
pISSN - 0012-1592
DOI - 10.1111/dgd.12700
Subject(s) - oryzias , crispr , cas9 , biology , genome editing , gene , mutagenesis , gene knockin , gene targeting , gene knockout , genetics , computational biology , plasmid , mutation
The CRISPR/Cas system offers new opportunities for targeted gene modifications in a wide range of organisms. In medaka ( Oryzias latipes ), a vertebrate model organism, a wild‐type Cas9‐based approach is commonly used to establish desired strains, however, its use in lethal genes is still challenging due to excess gene disruptions triggered by DNA double strand breaks (DSBs). To overcome this problem, we aimed to develop a new knock‐in system using Cas9 nickase (Cas9n) that can reduce DNA DSBs. We revealed that Cas9n allowed reduction of the DSB‐induced unwanted mutagenesis via non‐homologous end‐joining at both on‐ and off‐ target sites. Further, with a new donor plasmid (p2BaitD) that provides a linear template through Cas9n‐mediated nicks, we successfully integrated reporter cassettes via homology‐directed repair (HDR) into all three loci tested, including a lethal gene. In the experiment targeting the lethal gene, the combination of p2BaitD and Cas9n achieved higher survival rates than the Cas9‐based approach, which enabled the desired knock‐in founders. Additionally, through a technical blend of our knock‐in system with a recently developed One‐step mating protocol, we successfully established a homozygous knock‐in strain in one generation period. This study presents evidence of an effective method to generate an HDR‐mediated gene knock‐in in medaka and other organisms, which is useful for establishing screening platforms for genes or drugs toxicity or other applications.